Organon (OGN) has put Q1 2026 under the microscope with investors watching trailing numbers that show Q4 2025 revenue of US$1.5 billion, basic EPS of US$0.72 across the last twelve months, and a trailing net income of US$187 million after a large one off loss. Over recent quarters, the company has seen quarterly revenue move from US$1.59 billion in Q4 2024 to US$1.51 billion in Q4 2025, while basic EPS has ranged from US$0.34 in Q1 2025 up to US$1.39 in Q3 2024 and then to a loss of US$0.79 in Q4 2025. This sets up a story where compressed margins and a slimmer 3% net margin keep profitability squarely in focus.

See our full analysis for Organon.

With the latest earnings now on the table, the next step is to see how these margin driven results line up with the most common narratives investors rely on and where those stories might need updating.

Large one off loss drags 12 month margin to 3%

• Over the last twelve months, Organon generated US$6.2b in revenue and US$187 million in net income excluding extra items. This equates to a 3% net margin versus 13.5% a year earlier, after a US$348 million one off loss hit the period.
• Bulls point to margin improvement over time, but the current 3% net margin sits well below the bullish assumption of 11.1% today and the target of 15.7% in three years. This creates a clear gap between recent results and the optimistic story.
  • Consensus narrative talks about operational savings and a higher margin mix from products like Vtama and biosimilars. However, the trailing twelve month margin is still close to the low single digits.
  • For investors, the contrast between a 3% reported margin and the bullish margin path highlights how much of that upside case relies on future execution rather than what is visible in the latest numbers.

Organon's recent margin profile is a key reason bullish investors focus so heavily on future mix shift and cost programs, not just headline revenue trends. 🐂 Organon Bull Case

P/E sits at 18.6x with a wide gap to DCF fair value

• The stock trades on a trailing P/E of 18.6x, compared with 15.8x for the wider US pharmaceuticals group and 32.4x for the peer set. The DCF fair value in the data is US$86.39 against a current share price of US$13.25.
• Consensus narrative suggests the shares are priced for modest growth, yet the combination of a P/E above the industry average and a DCF fair value that is very large compared with the share price leaves investors weighing valuation upside against weaker profitability.
  • Forecasts in the data show earnings growth of about 13.6% a year and revenue growth of about 1.6% a year, which are both slower than the US market averages cited, even though the modeled DCF fair value is much higher than US$13.25.
  • This mix of slower forecast growth and a large DCF gap means investors need to judge how much faith to place in long term cash flow projections when the trailing net margin is only 3%.

Debt servicing risk stands out despite steady revenue base

• Across recent quarters, revenue has held in a tight band around US$1.5b to US$1.6b. However, the risk data flags that interest payments are not well covered by earnings, at the same time as net income excluding extra items swung from US$359 million in Q3 2024 to a loss of US$205 million in Q4 2025.
• Bears focus on this earnings volatility and weak interest coverage, arguing that heavy debt and pricing pressure on mature brands could limit flexibility even if revenue is relatively stable.
  • Risk summaries highlight large one off items and a sharp drop in trailing net margin from 13.5% to 3%, which supports the cautious view that cash flow available for debt service has been under strain.
  • With forecasts calling for only about 1.6% annual revenue growth in the data, bears see limited top line help if funding costs stay high or if further pricing headwinds emerge on off patent products.

Skeptical investors often focus on how interest coverage and margin swings feed into long term downside scenarios for the equity. 🐻 Organon Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Organon on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed on Organon after all that margin pressure and valuation debate, or feeling there might be more under the surface? Take a moment to check the numbers for yourself, weigh the latest earnings against your expectations, and then decide how you feel about the balance of 2 key rewards and 4 important warning signs

See What Else Is Out There

Organon's thin 3% net margin, earnings volatility, and weak interest coverage show how fragile results can feel when debt and profitability sit in tension.

If that mix makes you uneasy, compare it with companies screened for stronger financial footing and steadier earnings using the solid balance sheet and fundamentals stocks screener (44 results) today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.